Why Is Exemestane So Hard to Find? [Explained for 2026]

You showed up at the pharmacy with your exemestane prescription — and left empty-handed. Maybe the pharmacist said they were out of stock. Maybe they couldn't give you a timeline for when more would arrive. Whatever happened, you're now wondering: why is this medication so difficult to fill?

Exemestane (brand name Aromasin) is a steroidal aromatase inhibitor used to treat hormone receptor-positive breast cancer in postmenopausal women. It's not classified as a controlled substance, it's been generic since around 2018, and it's made by several manufacturers. So why can it be frustratingly hard to find at certain pharmacies? This guide breaks down the real reasons — and what you can do about it.

Is Exemestane Currently in Shortage?

As of 2026, exemestane is NOT on the FDA's official drug shortage list. The FDA Drug Shortages Database tracks medications with declared manufacturing or supply disruptions, and exemestane does not currently appear there. That means the problem patients are experiencing is usually not a national shortage — it's something more localized and often fixable.

That said, not being on the shortage list doesn't mean your specific pharmacy will always have it in stock. Pharmacies don't carry every medication from every manufacturer at all times. Stocking decisions are driven by demand, supplier contracts, profit margins, and shelf space — meaning a pharmacy down the street may have it when your regular pharmacy doesn't.

Why Do Individual Pharmacies Run Out of Exemestane?

Even without a national shortage, patients can face real difficulty filling exemestane for several reasons:

• Low stocking volume. Exemestane is prescribed far less frequently than anastrozole or letrozole — the other two aromatase inhibitors. Because pharmacies stock based on expected demand, smaller or independent pharmacies may only keep a small supply on hand and quickly run out.
• Supplier contract gaps. Generic exemestane is made by manufacturers including Alvogen, Breckenridge, Cipla, and Mylan. Each pharmacy chain may have an exclusive contract with one supplier — and if that supplier has a production delay, the pharmacy can't just switch suppliers mid-shipment cycle.
• Formulary and insurance friction. Some insurance plans require prior authorization for exemestane, or place it on a higher formulary tier than anastrozole or letrozole. When a prescription is flagged for prior auth, it can sit unprocessed at the pharmacy for days — making it feel like an availability problem when it's actually a coverage problem.
• Regional distribution gaps. Pharmaceutical distribution networks don't always reach every ZIP code equally. Rural pharmacies or those in underserved areas may face longer restock times than urban chain pharmacies.
• Manufacturer-specific production pauses. Individual generic manufacturers periodically pause production of lower-volume products to prioritize higher-demand drugs. This can create temporary but frustrating gaps in supply at pharmacies that depend on a single generic supplier.

Why Exemestane Is Less Common Than Other Aromatase Inhibitors

Understanding exemestane's market position helps explain why it can be harder to find than anastrozole or letrozole. All three are third-generation aromatase inhibitors, but they differ in important ways:

• Anastrozole and letrozole are nonsteroidal aromatase inhibitors — they're reversible, often cheaper (generic letrozole can be under $6/month with GoodRx), and are the most commonly prescribed first-line AIs.
• Exemestane is the only steroidal aromatase inhibitor. It works differently — permanently inactivating the aromatase enzyme rather than just blocking it temporarily. This makes it the only option for patients who have failed or cannot tolerate a nonsteroidal AI.
• Because exemestane is prescribed less often overall, it commands less shelf space and smaller safety stock quantities at most pharmacies — so when demand spikes, pharmacies run out faster.

Is It an Insurance or Prior Authorization Issue?

Many patients assume they're dealing with a supply problem when they're actually running into an insurance hurdle. Exemestane sometimes requires prior authorization on commercial insurance plans and Medicare Part D plans. Prior authorization means your insurance company needs documentation from your doctor before they agree to cover the drug. This can take 1–5 business days and can make your prescription appear 'stuck' at the pharmacy.

If you're not sure whether it's an insurance or a supply issue, ask your pharmacist directly: "Is this a stock problem, or is there an insurance authorization pending?" That one question can save you hours of confusion and help you take the right next step.

What Can You Do When Your Pharmacy Doesn't Have It?

Here are practical steps to take when you can't fill your exemestane prescription:

1. Call other pharmacies. Availability varies widely by location. Chain pharmacies (CVS, Walgreens, Kroger, Costco) and independent pharmacies may have different suppliers and different stock levels.
2. Ask your pharmacy to order it. Most pharmacies can order exemestane from their distributor within 1–3 business days if it's not in stock. Ask them to place the order and call you when it arrives.
3. Try a mail-order or specialty pharmacy. Mail-order pharmacies (CVS Caremark, Express Scripts, Optum Rx) often stock oncology medications more reliably because they serve large patient volumes.
4. Use medfinder. Instead of calling pharmacies yourself, medfinder.com does it for you — calling pharmacies near you to find which ones can fill your prescription, then texting you the results.
5. Talk to your oncologist. If exemestane is truly unavailable and you can't wait, your oncologist may consider whether switching to anastrozole or letrozole is clinically appropriate for your situation.

Should You Switch to Anastrozole or Letrozole?

This is a question only your oncologist can answer. All three aromatase inhibitors are similarly effective for most patients, but exemestane may be specifically prescribed because you switched from a nonsteroidal AI, because you couldn't tolerate anastrozole or letrozole, or because your oncologist has a clinical reason to prefer it for your case.

Do not switch medications or skip doses on your own. Interrupting hormonal therapy for breast cancer can have serious consequences. Always speak with your care team before making any changes to your treatment plan.

The Bottom Line

Exemestane is not in a national shortage, but individual pharmacies do run out due to low stocking levels, supplier contracts, and distribution gaps. The good news: the drug is available — you may just need to look at more than one pharmacy. Check out our guide on how to find exemestane in stock near you and our exemestane shortage update for 2026 for the latest information.